The Cell Therapy Bioprocsesing event taking place October 21-22, 2013 in Bethesda, Maryland. For more information on the event, download the agenda. If you'd like to join us, as a reader of this blog, you're can save 20% off the standard rate when you register to join us and mention code B13188JP20!
Leading up to the Cell Therapy BioProcessing event, we've interviewed several of the key stakeholders who helped shape this year's event. We'll start by looking at the recent interview we conduced with Event Chair Lee Buckler, the Founder and Managing Director of the Cell Therapy Group.Today, Buckler answers the question:
What is unique about the value of this Event when compared to other cell therapy conferences in the calendar?
Lee: So, I think when you look at other cell therapy conferences, cell therapy itself is a wide topic representing a number of different modalities and technologies. You’ve got the autologous vs. allogeneic, which themselves represent vastly different bioprocessing kind of platforms and technologies. You’ve got the different kinds of indications and you’ve got the different kinds of clinical markets. Most cell therapy conferences try to cover a wide rubric of clinical vs. technical vs. regulatory, reimbursement, commercial. So, the bioprocessing elements of any of those conferences gets fairly watered down or is fairly discreet, you know, restricted to one or two sessions. So, for us to be able to really get in a room together for a couple of days – people whose sole focus or who are very focused on the issues related to bioprocessing – is a unique opportunity to really focus on the topic that needs a fair amount of attention and has been identified as one of those that needs a fair amount of focus in order to make cell therapies commercially viable.
You can download Lee's full podcast here. Next week, Lee will look at some of the key challenges facing the cell therapy industry.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment